Louisiana Patients Could Lose Access to GLP-1 Weight-Loss Drugs as Coverage Vanishes Highlights Louisiana state employees are already prohibited from using GLP-1s for weight loss despite $200 million annual spending on diabetes coverage Over 41 million Americans lost commercial insurance coverage for Wegovy in 2026, with major insurers eliminating coverage nationwide Four states, including California and Pennsylvania, eliminated Medicaid coverage for obesity treatment between October 2025 and January 2026 Louisiana Medicaid provides limited coverage for one non-GLP-1 weight-loss drug but restrictions remain tight Patients face monthly costs ranging from $936 to $1,349 without insurance coverage BATON ROUGE, La
The synergy claim is mechanistic, derived from the three peptides acting on different nodes of overlapping pathways (VEGF, NF-kB, ECM remodeling)
Cell 187 , 70257044.e7034 (2024)
PlexusDx maintains a flat monthly rate across all three commitment tiers, eliminating the psychological burden of dose escalation costs that many patients experience with retail prescriptions
It also plays a role in taste and smell perception, which matters when appetite is already suppressed and food needs to be as appealing as possible
Fiber supplements such as psyllium husk or methylcellulose can address constipation, a common side effect of tirzepatide
